Association of Medicaid Expansion with Pancreatic Cancer Treatment and Outcomes: Evidence from the National Cancer Database
- 27 August 2021
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (1) , 342-351
Abstract
Socioeconomic- and demographic-based disparities exist in the treatment of pancreatic adenocarcinoma (PDAC). Medicaid expansion (ME) may have an impact onKeywords
This publication has 26 references indexed in Scilit:
- The 90-Day Mortality After Pancreatectomy for Cancer Is Double the 30-Day Mortality: More than 20,000 Resections From the National Cancer Data BaseAnnals of Surgical Oncology, 2014
- Who Receives Their Complex Cancer Surgery at Low-Volume Hospitals?Journal of the American College of Surgeons, 2012
- Trends in Hospital Volume and Operative Mortality for High-Risk SurgeryNew England Journal of Medicine, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Variations in Referral Patterns to High-Volume Centers for Pancreatic CancerJournal of the American College of Surgeons, 2009
- Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysisThe Lancet Oncology, 2008
- Hospital Volume and Late Survival After Cancer SurgeryAnnals of Surgery, 2007
- Treatment of Locally Advanced Pancreatic Cancer in the Real World: Population-Based Practices and EffectivenessJournal of Clinical Oncology, 2003
- Volume standards for high-risk surgical procedures: Potential benefits of the Leapfrog initiativeSurgery, 2001
- Multilevel analyses of neighbourhood socioeconomic context and health outcomes: a critical review: Table 1Journal of Epidemiology and Community Health, 2001